M/04/028 – Abbott / Aventis
Transaction details
proposal whereby Abbott Laboratories and several of its affiliates (“Abbott”) would acquire that part of the business of Aventis S.A. connected with the manufacture, distribution and sale of pharmaceutical products containing either Trandolapril or a combination of Trandolapril/Verapamil as the active ingredient (the “Proposed Transaction”).
| Notification date | Decision date |
|---|---|
| Wednesday May 5, 2004 | Wednesday, May 19, 2004 |
| Parties Involved | Business activities |
|---|---|
| Abbott | multinational corporation engaged in the manufacture and supply of a broad range of healthcare products and services. |
| Aventis | develops and markets pharmaceutical products. |
| Economic sector | Media merger |
|---|---|
| Pharmaceuticals | No |
| Submissions from third parties due by: | |
|---|---|
| Phase 1 | Phase 2 |
| Current status: Completed |
|---|
| Preliminary investigation (Phase 1) |
| Authorised Officer Assigned | Contact Details |
|---|---|
| . | . |
Media enquiries: MKC Communications: 01 7038600
Haven’t found what you’re looking for?
Scroll
Competition and Consumer Protection Commission
PO Box 12585, Dublin 1, D01 C576
Tel +353 (0)1 402 5500
Consumer helpline 01 402 5555